The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | How can time toxicity be reduced for patients in lung cancer clinical trials?
With the rise of trials assessing targeted therapies, especially in lung cancer, earlier endpoints are being measured, leading to more frequent biomarker testing in patients. Amanda Herrmann, MD, University of California San Diego, La Jolla, CA, highlights the need to reduce time toxicity patients experience in lung cancer clinical trials. Whilst simply receiving treatment in the clinic or in a clinical trial requires a time commitment, clinicians need to take into account the needs of patients when designing clinical trials. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
